Eli Lilly is upgraded to Buy after a 13% pullback and strong Q4 guidance, with potential for 25% topline growth in 2026.

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap ...

A flag flies above the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and ...

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly. Lilly's tirzepatide franchise is ...

"Regulatory reviews are ongoing in over 40 countries" and "we plan to submit Foundayo in the U.S. for type 2 diabetes later this quarter" (Chairman & CEO Ricks). "Revenue grew 56% compared to Q1 2025" ...

Amazon (NASDAQ: AMZN) just made a quiet move that could reshape how Americans access weight-loss drugs. On April 9, 2026, it announced that its pharmacy unit will stock new GLP-1 weight-loss pill ...

The Dow Jones Industrial Average jumped more than 700 points to close at 49,652, powered by gains in industrial and healthcare stocks despite weakness in mega-cap tech. Caterpillar and Eli Lilly ...

A simple outpatient procedure currently used for type 2 diabetes patients in Europe can help those on Eli Lilly’s obesity ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

The GLP-1 weight-loss category exploded into a multi-billion-dollar opportunity that blends medication access with ongoing ...

With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British biotech’s future.

A 10-year investing horizon shifts the conversation away from short-term noise toward something more durable: which ...